PUBLICATION ARCHIVES
M402AACR 2010
He Zhou, Sucharita Roy, Edward Cochran, Radouane Zouaoui, Juliane Karlgren, Nancy Dussault, Rain YQ Kwan, Jay Duffner, Ganlin Zhao, Sean Smith, Zoya Galcheva-Gargova, Erick Moy, Marishka Barnes, Chris Honan, Chia Lin Chu, Yi Wei Qi, Tanmoy Ganguly, Birgit Schultes, Ganesh Venkataraman, Takashi Kei Kishimoto
M402 –A novel heparan sulfate proteoglycan mimetic targeting tumor-host interactions
Martijn P. Lolkema1,4, Michelle Lockley1,2, He Zhou3, Jay Duffner3, Takashi Kei Kishimoto3, David A. Tuveson1
1. Cancer Research UK, Cambridge Research Institute, Cambridge, UK 2. Barts and the London School of Medicine, London, UK 3. Momenta Pharmaceuticals, Cambridge, MA USA 4. University Medical Centre Utrecht, The Netherlands
M402, a Novel Heparan Sulfate Mimetic, Synergizes with Gemcitabine to Improve Survival and Reduce Metastasis and Epithelial-to-Mesenchymal Transition (EMT) in a Genetically Engineered Mouse Model for Pancreatic Cancer
AACR 2009
ChiaLin Chu, Jay Duffner, Nancy Dussault, Alison Long, SucharitaRoy, RadouaneZouaoui, Erick Moy, He Zhou, Birgit C. Schultes, Takashi K. Kishimoto.
M-ONC 402, A novel non-anticoagulant heparin, inhibits P-Selectin function
and metastatic seeding of tumor cells in mice.
He Zhou, Nancy Dussault, Edward Cochran, Rain Kwan, Juliane Karlgren, Marishka Barnes, Sucharita Roy,
Radouane Zouaoui, Jay Duffner, Chia Lin Chu, Sean Smith, Chris Honan, Zoya Galcheva-Gargova, Yi Wei Qi, Tanmoy Ganguly, Birgit Schultes, Kei Kishimoto.
M-ONC 402-a non anticoagulant low molecular weight heparin inhibits tumor metastasis.
Selected Publications Momenta Featured in The New England Journal of Medicine
Read the article published online April 23, 2008 on the The New England Journal of Medicine website – “Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System”.
Click Here to Read the Article »
Momenta Featured in Nature Biotechnology
Read the article published online April 23, 2008 on the Nature Biotechnology website - "Oversulfated chondroitin sulfate is a contaminant in
heparin associated with adverse clinical events"
Click Here to Read the Article »